Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Establishment of a new human pneumococcal standard reference serum, 007sp.

Goldblatt D, Plikaytis BD, Akkoyunlu M, Antonello J, Ashton L, Blake M, Burton R, Care R, Durant N, Feavers I, Fernsten P, Fievet F, Giardina P, Jansen K, Katz L, Kierstead L, Lee L, Lin J, Maisonneuve J, Nahm MH, Raab J, Romero-Steiner S, Rose C, Schmidt D, Stapleton J, Carlone GM.

Clin Vaccine Immunol. 2011 Oct;18(10):1728-36. doi: 10.1128/CVI.05252-11. Epub 2011 Aug 18.

2.

Vaccination with Ad5 vectors expands Ad5-specific CD8 T cells without altering memory phenotype or functionality.

Hutnick NA, Carnathan DG, Dubey SA, Cox KS, Kierstead L, Makadonas G, Ratcliffe SJ, Lasaro MO, Robertson MN, Casimiro DR, Ertl HC, Betts MR.

PLoS One. 2010 Dec 22;5(12):e14385. doi: 10.1371/journal.pone.0014385.

3.

Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.

Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV, Self S, Turner K, Sanchez J, Pitisuttithum P, Duerr A, Dubey S, Kierstead L, Casimiro D, Hammer SM; for the Merck V520-018/HIV Vaccine Trials Network 050 Study Team.

AIDS Res Hum Retroviruses. 2010 Nov 23. [Epub ahead of print]

4.

Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.

Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS, Casimiro DR, Shiver JW, Robertson MN, Quirk EK, Mehrotra DV.

J Infect Dis. 2010 Jan 1;201(1):132-41. doi: 10.1086/648591.

PMID:
19929694
5.

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.

Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, Wolfe ND, Aste-Amezaga M, Casimiro DR, Coplan P, Straus WL, Shiver JW.

Vaccine. 2010 Jan 22;28(4):950-7. doi: 10.1016/j.vaccine.2009.10.145. Epub 2009 Nov 17.

PMID:
19925902
6.

Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells.

Hutnick NA, Carnathan DG, Dubey SA, Makedonas G, Cox KS, Kierstead L, Ratcliffe SJ, Robertson MN, Casimiro DR, Ertl HC, Betts MR.

Nat Med. 2009 Aug;15(8):876-8. doi: 10.1038/nm.1989. Epub 2009 Jul 20. Erratum in: Nat Med. 2009 Nov;15(11):1333. Makedonas, George [added].

7.

Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.

Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, Mulligan MJ, Priddy FH, Dubey SA, Kierstead LS, Sun X, Casimiro DR, DiNubile MJ, Shiver JW, Leavitt RY, Mehrotra DV; Merck V520-007/012 Study Teams.

AIDS Res Hum Retroviruses. 2009 Jan;25(1):103-14. doi: 10.1089/aid.2008.0212.

8.

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR; Step Study Protocol Team.

Lancet. 2008 Nov 29;372(9653):1894-1905. doi: 10.1016/S0140-6736(08)61592-5. Epub 2008 Nov 13.

9.

Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E; Merck V520-016 Study Group.

Clin Infect Dis. 2008 Jun 1;46(11):1769-81. doi: 10.1086/587993.

PMID:
18433307
10.

Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay.

Dubey S, Clair J, Fu TM, Guan L, Long R, Mogg R, Anderson K, Collins KB, Gaunt C, Fernandez VR, Zhu L, Kierstead L, Thaler S, Gupta SB, Straus W, Mehrotra D, Tobery TW, Casimiro DR, Shiver JW.

J Acquir Immune Defic Syndr. 2007 May 1;45(1):20-7.

PMID:
17310936
11.

Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC.

Kierstead LS, Dubey S, Meyer B, Tobery TW, Mogg R, Fernandez VR, Long R, Guan L, Gaunt C, Collins K, Sykes KJ, Mehrotra DV, Chirmule N, Shiver JW, Casimiro DR.

AIDS Res Hum Retroviruses. 2007 Jan;23(1):86-92.

PMID:
17263637
12.

Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates.

Capone S, Zampaglione I, Vitelli A, Pezzanera M, Kierstead L, Burns J, Ruggeri L, Arcuri M, Cappelletti M, Meola A, Ercole BB, Tafi R, Santini C, Luzzago A, Fu TM, Colloca S, Ciliberto G, Cortese R, Nicosia A, Fattori E, Folgori A.

J Immunol. 2006 Nov 15;177(10):7462-71.

13.

MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.

Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Brusic V, Sidney J, Sette A, Logan TF, Kasamon YL, Slingluff CL Jr, Kirkwood JM, Storkus WJ.

Clin Cancer Res. 2003 Mar;9(3):947-54.

14.

Memory T cells and vaccines.

Esser MT, Marchese RD, Kierstead LS, Tussey LG, Wang F, Chirmule N, Washabaugh MW.

Vaccine. 2003 Jan 17;21(5-6):419-30. Review.

PMID:
12531640
15.

Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.

Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW, Storkus WJ.

J Exp Med. 2002 Sep 2;196(5):619-28.

16.

gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells.

Kierstead LS, Ranieri E, Olson W, Brusic V, Sidney J, Sette A, Kasamon YL, Slingluff CL Jr, Kirkwood JM, Storkus WJ.

Br J Cancer. 2001 Nov 30;85(11):1738-45.

17.

Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading.

Ranieri E, Kierstead LS, Zarour H, Kirkwood JM, Lotze MT, Whiteside T, Storkus WJ.

Immunol Invest. 2000 May;29(2):121-5. No abstract available.

PMID:
10854179
18.

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.

Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr, Sidney J, Sette A, Storkus WJ.

Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):400-5.

19.

Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination.

Ranieri E, Herr W, Gambotto A, Olson W, Rowe D, Robbins PD, Kierstead LS, Watkins SC, Gesualdo L, Storkus WJ.

J Virol. 1999 Dec;73(12):10416-25.

20.

Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood.

Herr W, Ranieri E, Gambotto A, Kierstead LS, Amoscato AA, Gesualdo L, Storkus WJ.

Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12033-8.

21.

Expression of the Cell Adhesion Molecule CD44 in Human Lung Tumors and Cell Lines.

Resnick NM, Clarke MR, Siegfried JM, Landreneau R, Asman DC, Ge L, Kierstead LS, Dougherty GD, Cooper DL.

Mol Diagn. 1998 Jun;3(2):93-103.

PMID:
10029660

Supplemental Content

Loading ...
Support Center